How Long Do Retatrutide Nausea and Stomach Side Effects Last?

What do retatrutide trials report about stomach side effects?

The published trials report gastrointestinal events, but they do not establish how long an individual episode lasts. In the phase 2 trial enrolling 338 adults with obesity over 48 weeks, events were dose-related and mostly mild to moderate. That describes frequency and severity within a trial, not a recovery deadline. [Jastreboff 2023, PMID 37366315; NCT04881760]

The phase 2 trial in participants with type 2 diabetes reported nausea, diarrhea, vomiting and constipation within its mild-to-moderate gastrointestinal event category over 36 weeks. The figures below refer to that combined category, not nausea alone. [Rosenstock 2023, PMID 37385280; NCT04867785]

The published phase 3 TRANSCEND-T2D-1 trial followed 537 adults with type 2 diabetes for 40 weeks. Its report describes the most frequent adverse events as generally mild-to-moderate gastrointestinal events that subsided over time. It does not assign a duration to nausea, vomiting or diarrhea separately. [Bajaj 2026, PMID 42250575; NCT06354660]

When did events appear, and when did they decrease?

Tirzepatide records place most nausea, vomiting and diarrhea during dose escalation and describe a decrease over time; the retatrutide report gives the broader statement that gastrointestinal events subsided. These are observations from separate trial programs. [DailyMed Mounjaro and Zepbound, section 6.1; PMID 42250575]

The Mounjaro label statement concerns pooled placebo-controlled adult trials in participants with type 2 diabetes. Zepbound reports the same timing pattern in its weight-management trial pool. Neither statement gives a fixed duration for an individual episode. [DailyMed Mounjaro and Zepbound, section 6.1]

The pooled SURMOUNT analysis specifies a 20-week dose-escalation period in each included trial and reports that gastrointestinal events occurred primarily during that period and diminished over time. An escalation period is a study-design interval, not the duration of nausea. It cannot establish that every episode lasted throughout that interval or ended when it finished. It also cannot supply a retatrutide stopping week. [Rubino 2025, PMID 39789843; PMC11885085]

How severe were the events, and did participants stop?

The reports predominantly describe mild or moderate events, while also recording discontinuations. In the EU Mounjaro product information, gastrointestinal reactions in the pooled adult placebo-controlled phase 3 trials in participants with type 2 diabetes were classified as mild in 74% and moderate in 23.3%. The separate weight-management trial pool reports mild in 60.8% and moderate in 34.6%. These are severity distributions, not percentages of all participants who developed nausea. [EMA Mounjaro product information, section 4.8]

The SURMOUNT analysis says gastrointestinal events rarely led to discontinuation. Retatrutide sponsor toplines also report discontinuations, but their cited figures are for adverse events overall. They cannot be relabeled as nausea-specific discontinuations or used to calculate symptom duration. Severity, discontinuation and resolution answer different questions. [Rubino 2025, PMID 39789843; Lilly TRIUMPH-1, NCT05929066; TRIUMPH-4, NCT05931367]

What do the retatrutide sponsor toplines add?

The TRIUMPH toplines add event frequencies and adverse-event discontinuation figures, not a symptom-resolution timeline. TRIUMPH-1 reports nausea, diarrhea, constipation and vomiting by trial arm; TRIUMPH-4 reports these events in the enrolled knee osteoarthritis population. [Lilly TRIUMPH-1, NCT05929066; TRIUMPH-4, NCT05931367]

Their source status matters: the registry checks on 2026-09-12 recorded both trials as completed without posted results. The available findings here are sponsor toplines, distinct from the published TRANSCEND-T2D-1 report. [ClinicalTrials.gov NCT05929066, NCT05931367; PMID 42250575]

A wording trap deserves attention. In the TRIUMPH-1 release, the statement that events were generally mild to moderate and mostly resolved concerns dysesthesia and urinary tract infections. It does not describe the gastrointestinal events. Applying that sentence to nausea would misstate the source. [Lilly TRIUMPH-1, NCT05929066]

Why is there no reliable number of days or weeks?

The searched records report incidence or qualitative change, without the resolution measurements needed for that number. On 2026-09-12, PubMed searching retatrutide[tiab] AND (duration[tiab] OR resolution[tiab] OR resolved[tiab]) AND (nausea[tiab] OR vomiting[tiab] OR gastrointestinal[tiab]) returned 6 hits, none reporting mean or median time to resolution. The broader retatrutide[tiab] AND (nausea[tiab] OR gastrointestinal[tiab]) search returned 44 hits without a week-by-week resolution curve in the primary trial publications.

The phase 2 registry uses the cumulative reporting window “Baseline Through End of Safety Follow-up (Up to 52 Weeks).” That is the observation window, not the time symptoms lasted. [ClinicalTrials.gov NCT04881760, Adverse Events module]

Gastric-emptying research does not fill the gap. Tirzepatide's measured delay diminished with repeated dosing in healthy participants, with residual delay in participants with type 2 diabetes. That finding cannot be transferred to retatrutide or converted into a nausea timeline. The retatrutide gastric-emptying paper had no PubMed abstract available in the documented retrieval, so no quantitative estimate is available here. [Urva 2020, PMID 32519795; Urva 2023, PMID 37311727, retrieval 2026-09-12]

Individual symptoms belong in a discussion with a clinician.

Products mentioned

Sources

1. Jastreboff, 2023, NEJM, retatrutide phase 2 obesity trial. PMID 37366315; NCT04881760.
2. Rosenstock, 2023, Lancet, retatrutide phase 2 diabetes trial. PMID 37385280; NCT04867785.
3. Bajaj, 2026, Lancet, TRANSCEND-T2D-1. PMID 42250575; NCT06354660.
4. DailyMed, 2026-09-02, MOUNJARO, section 6.1. SPL setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
5. DailyMed, 2026-09-02, ZEPBOUND, section 6.1. SPL setid 487cd7e7-434c-4925-99fa-aa80b1cc776b.
6. EMA, Mounjaro product information, section 4.8. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
7. Rubino, 2025, Diabetes Obes Metab, pooled SURMOUNT post hoc. PMID 39789843; PMC11885085.
8. Lilly, 2026-05-21, TRIUMPH-1 topline. NCT05929066.
9. Lilly, 2025-12-11, TRIUMPH-4 topline. NCT05931367.
10. ClinicalTrials.gov, 2026-09-12, phase 2 registry record, Adverse Events module. NCT04881760.
11. ClinicalTrials.gov, 2026-09-12, TRIUMPH-1 and TRIUMPH-4 registry result-status checks. NCT05929066; NCT05931367.
12. Urva, 2020, Diabetes Obes Metab, tirzepatide gastric-emptying study. PMID 32519795; PMC7539915.
13. Urva, 2023, Diabetes Obes Metab, “The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.” PMID 37311727; DOI 10.1111/dom.15167.
14. PeptidesDirect, 2026-09-12. Internal Reddit corpus audit, compound plus symptom plus duration regex over title and selftext: question-posts.jsonl and delta2/questions.json.

Research use only. Retatrutide is supplied strictly for in-vitro research. Nothing in this article is an application protocol, a recommendation or medical advice.